{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:40:06Z","timestamp":1751373606623,"version":"3.41.0"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This study investigates the impact of hormone therapy (HT) on the diagnostic performance of <jats:sup>18<\/jats:sup>F\u2010piflufolastat PET\/CT in OSPREY (NCT02981368) cohort B patients with recurrent or metastatic prostate cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:sup>18<\/jats:sup>F\u2010piflufolastat PET\/CT was evaluated in OSPREY cohort B patients (<jats:italic>n<\/jats:italic>\u2009=\u2009117 men) with elevated prostate\u2010specific antigen (PSA) levels and suspected local recurrence or metastatic disease on baseline conventional imaging. Patients were stratified based on HT status, and sensitivity and positive predictive value (PPV) were determined for the subset of 93 patients with evaluable pathology. Baseline serum PSA and testosterone levels were determined within 30 days before dosing using standardized laboratory methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In OSPREY cohort B, 34.4% of patients (32\/93) were on at least one concomitant HT with a median exposure duration of 15.5 months. The median baseline PSA and testosterone levels for patients on concurrent HT (<jats:italic>n<\/jats:italic>\u2009=\u200932) were 31.6\u2009ng\/mL and 9\u2009ng\/dL, respectively. For patients not on concurrent therapy (<jats:italic>n<\/jats:italic>\u2009=\u200961), median PSA and testosterone levels were 6.1\u2009ng\/mL and 317.35\u2009ng\/dL, respectively. The median sensitivity of <jats:sup>18<\/jats:sup>F\u2010piflufolastat PET\/CT across three readers was 96.4% (95%CI: 80.8%\u2013100%) in patients receiving concurrent HT and 95.4% (95%CI: 83.7%\u201399.6%) in patients not receiving concurrent HT. A modest increase in median PPV was observed in patients receiving concomitant HT (median of three readers: 90.0% [95%CI: 73.6, 97.3]) compared to patients not receiving concomitant therapy (median of three readers: 77.4% [95%CI: 66.1, 88.6]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The diagnostic performance of <jats:sup>18<\/jats:sup>F\u2010piflufolastat PET\/CT was unaffected by concomitant HT in OSPREY cohort B patients with recurrent and\/or metastatic prostate cancer.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24909","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:24:15Z","timestamp":1746422655000},"page":"1005-1015","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Concomitant Hormone Therapy on the Diagnostic Performance of <sup>18<\/sup>F\u2010Piflufolastat PET\/CT in Prostate Cancer Patients: A Sub\u2010Group Analysis of OSPREY Cohort B"],"prefix":"10.1002","volume":"85","author":[{"given":"Lawrence","family":"Saperstein","sequence":"first","affiliation":[{"name":"Department of Radiology and Biomedical Imaging Yale School of Medicine  Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-4694","authenticated-orcid":false,"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Radiology University of North Carolina School of Medicine Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[{"name":"Milton and Carroll Petrie Department of Urology Icahn School of Medicine at Mount Sinai New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Pienta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sidney Kimmell Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry A.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Mallinckrodt Institute of Radiology and Siteman Cancer Center Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saradha","family":"Baskaran","sequence":"additional","affiliation":[{"name":"Lantheus Bedford Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Stambler","sequence":"additional","affiliation":[{"name":"Lantheus Bedford Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent A.","family":"DiPippo","sequence":"additional","affiliation":[{"name":"Lantheus Bedford Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela S.","family":"Denes","sequence":"additional","affiliation":[{"name":"Lantheus Bedford Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"PYLARIFY [Package Insert]. Progenics Pharmaceuticals Inc a Lantheus Company."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001698"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/JME-14-0203"},{"key":"e_1_2_12_5_1","unstructured":"NCCN Guidelines for Patients Advanced\u2010Stage Prostate Cancer published2024."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102992"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22910"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.181800"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04529-8"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031046"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.03.010"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4079-z"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<407::AID-CNCR23>3.0.CO;2-0"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259069"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4923"},{"issue":"10","key":"e_1_2_12_19_1","first-page":"13","article-title":"Overview of Prostate\u2010Specific Membrane Antigen","volume":"6","author":"Chang S. S.","year":"2004","journal-title":"Reviews in Urology"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00278-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.104661"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0850-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102738"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0145-8"},{"issue":"1","key":"e_1_2_12_25_1","first-page":"1357","article-title":"The Role of Castrate Status and Androgen Deprivation Therapy in PSMA\u2010Based 18F\u2010DCFPyL PET\/CT Imaging of Metastatic Prostate Cancer Patients","volume":"62","author":"Mena E.","year":"2021","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-01048-4"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04674-0"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-021-01605-0"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:25:45Z","timestamp":1751372745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/pros.24909"],"URL":"https:\/\/doi.org\/10.1002\/pros.24909","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"type":"print","value":"0270-4137"},{"type":"electronic","value":"1097-0045"}],"subject":[],"published":{"date-parts":[[2025,5,4]]},"assertion":[{"value":"2025-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}